Home FDA FDA Guidance–Rare Diseases: Natural History Studies for Drug Development

FDA Guidance–Rare Diseases: Natural History Studies for Drug Development

302
0
Rare Disease

The Food and Drug Administration (FDA) has released a draft guidance titled “Rare Diseases: Natural History Studies for Drug Development” with the intention to inform both the design and execution of natural history studies to support the development of safe and effective rare disease treatments. Significant progress aside, few rare diseases have approved therapies. A great unmet need now moves the FDA into action. Follow the link to read the actual guidance.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.